{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:42Z","timestamp":1794018582534,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic review to evaluate the monthly risk of grade III\/IV infection, pneumonia, and neutropenia in patients with myeloma enrolled in randomized clinical trials (RCTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The risk of grade III or higher infection, pneumonia, and neutropenia persists among all phases of treatment. There was no statistical difference in grade III or higher infection, pneumonia, and neutropenia between frontline and relapsed\/refractory setting. In the maintenance setting, the complications of infection, pneumonia, and neutropenia were low, but not negligible. Three-drug regimens were no more likely than two-drug regimens to have an increased risk of Grade III or higher infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first study to quantify the monthly risk of grade III or higher infection, pneumonia, and neutropenia across different treatment regimens in the frontline, maintenance, and relapsed\/refractory settings. The results of our systematic review demonstrate a significant risk for severe infection, pneumonia, and neutropenia in patients with MM. Further studies are needed to determine the value of antibiotic prophylaxis in a broader myeloma patient population, as well as other approaches that will further mitigate the morbidity and mortality related to infection in this vulnerable patient population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08451-x","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T02:02:26Z","timestamp":1624672946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019"],"prefix":"10.1186","volume":"21","author":[{"given":"Nicole","family":"Balmaceda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viveksandeep Thoguluva","family":"Chandrasekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McClune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneela","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"1","key":"8451_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107\u201313. https:\/\/doi.org\/10.3324\/haematol.2014.107714.","journal-title":"Haematologica"},{"issue":"36","key":"8451_CR2","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council adult Leukaemia working party. J Clin Oncol. 2005;23(36):9219\u201326. https:\/\/doi.org\/10.1200\/JCO.2005.03.2086.","journal-title":"J Clin Oncol"},{"issue":"8","key":"8451_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211\u201325. https:\/\/doi.org\/10.1086\/605664.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"8451_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1080\/10428190500472503","volume":"47","author":"P Sch\u00fctt","year":"2006","unstructured":"Sch\u00fctt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, M\u00fcller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570\u201382. https:\/\/doi.org\/10.1080\/10428190500472503.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"8451_CR5","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1002\/ajh.23932","volume":"90","author":"MO Holmstrom","year":"2015","unstructured":"Holmstrom MO, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish myeloma database. Am J Hematol. 2015;90(4):E73\u20134. https:\/\/doi.org\/10.1002\/ajh.23932.","journal-title":"Am J Hematol"},{"issue":"50","key":"8451_CR6","doi-asserted-by":"publisher","first-page":"e2305","DOI":"10.1097\/MD.0000000000002305","volume":"94","author":"P Hsu","year":"2015","unstructured":"Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, et al. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine (Baltimore). 2015;94(50):e2305. https:\/\/doi.org\/10.1097\/MD.0000000000002305.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"8451_CR7","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","volume":"24","author":"F Davies","year":"2010","unstructured":"Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24(Suppl 1):S13\u20139. https:\/\/doi.org\/10.1016\/S0268-960X(10)70004-7.","journal-title":"Blood Rev"},{"issue":"28","key":"8451_CR8","doi-asserted-by":"publisher","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget. 2017;8(28):46593\u2013600. https:\/\/doi.org\/10.18632\/oncotarget.16235.","journal-title":"Oncotarget"},{"issue":"24","key":"8451_CR9","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398. https:\/\/doi.org\/10.1056\/NEJMoa043445.","journal-title":"N Engl J Med"},{"issue":"7","key":"8451_CR10","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100.","journal-title":"PLoS Med"},{"issue":"oct18 2","key":"8451_CR11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"2","key":"8451_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/jrsm.38","volume":"2","author":"JJ Shuster","year":"2011","unstructured":"Shuster JJ. Review: Cochrane handbook for systematic reviews for interventions, version 5.1.0, published 3\/2011. Res Synth Methods. 2011;2(2):126\u201330. https:\/\/doi.org\/10.1002\/jrsm.38 Julian P.T. Higgins and Sally green, editors.","journal-title":"Res Synth Methods"},{"issue":"7414","key":"8451_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"33","key":"8451_CR14","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Community-based phase IIIB trial of three UPFRONT Bortezomib-based myeloma regimens. J Clin Oncol. 2015;33(33):3921\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.58.7618.","journal-title":"J Clin Oncol"},{"issue":"10218","key":"8451_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3.","journal-title":"Lancet"},{"issue":"10","key":"8451_CR16","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/j.clml.2019.09.583","volume":"19","author":"P Voorhees","year":"2019","unstructured":"Voorhees P, Kaufman JL, Laubach J, Sborov D, Reeves B, Rodriguez C, et al. Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Clin Lymphoma Myeloma Leukemia. 2019;19(10):e353\u20134. https:\/\/doi.org\/10.1016\/j.clml.2019.09.583.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"16","key":"8451_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hern\u00e1ndez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337\u201345. https:\/\/doi.org\/10.1182\/blood.2019000241.","journal-title":"Blood"},{"issue":"10192","key":"8451_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1.","journal-title":"Lancet"},{"issue":"9","key":"8451_CR19","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1080\/10428194.2019.1579322","volume":"60","author":"N Horvath","year":"2019","unstructured":"Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, et al. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leuk Lymphoma. 2019;60(9):2122\u201333. https:\/\/doi.org\/10.1080\/10428194.2019.1579322.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"8451_CR20","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1817249.","journal-title":"N Engl J Med"},{"issue":"10068","key":"8451_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(16)31594-X.","journal-title":"Lancet"},{"issue":"7","key":"8451_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.55","volume":"6","author":"SJ Jacobus","year":"2016","unstructured":"Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS, et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J. 2016;6(7):e448. https:\/\/doi.org\/10.1038\/bcj.2016.55.","journal-title":"Blood Cancer J"},{"issue":"18","key":"8451_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953\u201363. https:\/\/doi.org\/10.1182\/blood-2018-09-874396.","journal-title":"Blood"},{"issue":"12","key":"8451_CR24","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","volume":"6","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(12):e616\u201329. https:\/\/doi.org\/10.1016\/S2352-3026(19)30167-X.","journal-title":"Lancet Haematol"},{"issue":"7","key":"8451_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1505654.","journal-title":"N Engl J Med"},{"issue":"9","key":"8451_CR26","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","volume":"6","author":"MV Mateos","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459\u201369. https:\/\/doi.org\/10.1016\/S2352-3026(19)30110-3.","journal-title":"Lancet Haematol"},{"issue":"6","key":"8451_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(19)30152-4.","journal-title":"Lancet Oncol"},{"issue":"7","key":"8451_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (a.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(18)30354-1.","journal-title":"Lancet Oncol"},{"issue":"19","key":"8451_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1805762.","journal-title":"N Engl J Med"},{"issue":"12","key":"8451_CR30","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088\u201396. https:\/\/doi.org\/10.3324\/haematol.2018.194282.","journal-title":"Haematologica"},{"issue":"12","key":"8451_CR31","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079\u201387. https:\/\/doi.org\/10.3324\/haematol.2018.194118.","journal-title":"Haematologica"},{"issue":"1","key":"8451_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","volume":"31","author":"R H\u00e1jek","year":"2017","unstructured":"H\u00e1jek R, Masszi T, Petrucci MT, Palumbo A, Rosi\u00f1ol L, Nagler A, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31(1):107\u201314. https:\/\/doi.org\/10.1038\/leu.2016.176.","journal-title":"Leukemia"},{"issue":"12","key":"8451_CR33","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","volume":"2","author":"PG Richardson","year":"2015","unstructured":"Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516\u201327. https:\/\/doi.org\/10.1016\/S2352-3026(15)00197-0.","journal-title":"Lancet Haematol"},{"issue":"9","key":"8451_CR34","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00277-019-03739-2","volume":"98","author":"I Spicka","year":"2019","unstructured":"Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, et al. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed\/refractory multiple myeloma. Ann Hematol. 2019;98(9):2139\u201350. https:\/\/doi.org\/10.1007\/s00277-019-03739-2.","journal-title":"Ann Hematol"},{"issue":"10214","key":"8451_CR35","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107. https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5.","journal-title":"Lancet"},{"issue":"Supplement_1","key":"8451_CR36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2019-126015","volume":"134","author":"P Moreau","year":"2019","unstructured":"Moreau P, et al. Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma. Blood. 2019;134(Supplement_1):1888.","journal-title":"Blood"},{"issue":"1","key":"8451_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7.","journal-title":"Lancet Oncol"},{"issue":"9","key":"8451_CR38","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","volume":"6","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e448\u201358. https:\/\/doi.org\/10.1016\/S2352-3026(19)30109-7.","journal-title":"Lancet Haematol"},{"issue":"17","key":"8451_CR39","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1516282.","journal-title":"N Engl J Med"},{"issue":"5","key":"8451_CR40","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370\u201380. https:\/\/doi.org\/10.1016\/S2352-3026(20)30070-3.","journal-title":"Lancet Haematol"},{"issue":"3, Supplement","key":"8451_CR41","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.bbmt.2018.12.087","volume":"25","author":"G Morgan","year":"2019","unstructured":"Morgan G, et al. Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Biol Blood Marrow Transplant. 2019;25(3, Supplement):S19\u201320.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"8451_CR42","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3324\/haematol.2019.226407","volume":"105","author":"S Bringhen","year":"2020","unstructured":"Bringhen S, D\u2019Agostino M, Paris L, Ballanti S, Pescosta N, Spada S, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020;105(7):1937\u201347. https:\/\/doi.org\/10.3324\/haematol.2019.226407.","journal-title":"Haematologica"},{"issue":"9","key":"8451_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","volume":"127","author":"S Zweegman","year":"2016","unstructured":"Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GMJ, Levin MD, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;127(9):1109\u201316. https:\/\/doi.org\/10.1182\/blood-2015-11-679415.","journal-title":"Blood"},{"issue":"16","key":"8451_CR44","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(15)00389-7.","journal-title":"Lancet Oncol"},{"issue":"21","key":"8451_CR45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.V118.21.634.634","volume":"118","author":"PG Richardson","year":"2011","unstructured":"Richardson PG, et al. Randomized, open label phase 1\/2 study of Pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes Lenalidomide (LEN) and Bortezomib (BORT): phase 2 results. Blood. 2011;118(21):634.","journal-title":"Blood"},{"key":"8451_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2013.100982","volume":"99","author":"JF San Miguel","year":"2014","unstructured":"San Miguel JF, et al. MM-003, a phase 3 study of pomalidomide+low-dose dexamethasone vs. High-dose dexamethasone in refractory or relapsed and refractory multiple myeloma: Outcomes by prior therapy and response depth. Haematologica. 2014;99:110.","journal-title":"Haematologica"},{"issue":"1","key":"8451_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(09)70284-0.","journal-title":"Lancet Oncol"},{"issue":"5","key":"8451_CR48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12185-014-1672-1","volume":"100","author":"SH Jung","year":"2014","unstructured":"Jung SH, Kang SJ, Jang HC, Ahn JS, Yang DH, Lee SS, et al. Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. Int J Hematol. 2014;100(5):473\u20137. https:\/\/doi.org\/10.1007\/s12185-014-1672-1.","journal-title":"Int J Hematol"},{"issue":"12","key":"8451_CR49","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20(12):1760\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30506-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"8451_CR50","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1903455.","journal-title":"N Engl J Med"},{"issue":"8","key":"8451_CR51","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood-2014-02-482612","volume":"124","author":"C Gibson","year":"2014","unstructured":"Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood. 2014;124(8) quiz 1378:1251\u20138. https:\/\/doi.org\/10.1182\/blood-2014-02-482612.","journal-title":"Blood"},{"issue":"6","key":"8451_CR52","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","volume":"97","author":"M Chen","year":"2018","unstructured":"Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97(6):925\u201344. https:\/\/doi.org\/10.1007\/s00277-018-3284-y.","journal-title":"Ann Hematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08451-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08451-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08451-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T02:03:41Z","timestamp":1624673021000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08451-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8451"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08451-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"24 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Manuscript does not report or involve the use of animal or human data or tissue. Meta-analysis was performed. Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interests to disclose, other than the following for Siddhartha Ganguly (SG) and Joseph McGuirk (JM).SG: Daiichi Sankyo: Research Funding; Seattle Genetics: Speakers Bureau; Kite Pharma: Honoraria, Other: Advisory Board; Janssen: Honoraria.JM: Kite Pharmaceuticals: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bellicum Pharmaceuticals: Research Funding; Astellas: Research Funding; Juno Therapeutics: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Fresenius Biotech: Research Funding; Gamida Cell: Research Funding; Pluristem Ltd.: Research Funding; Articulate Science.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"730"}}